Q2 FY2026 EarningsQ2 FY26 results presented a mixed performance against consensus, with zero revenue as expected for a clinical-stage firm. While EBIT missed expectations by 12.37% due to stock-based compensation modifications, EPS beat the consensus of -$0.26 by $0.002, supported by a significantly expanded share count following an April underwritten offering. Net loss was $13.95M vs. the $12.88M expected, driven by increased R&D and internal personnel costs.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sagimet Biosciences(SGMT) the EBIT is -15.82 M (-32.65%), Miss estimate;the EPS is -0.26 (+18.75%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B32.65%
-0.01B18.04%
-0.00B14.61%
EPSMiss expectations
-0.2618.75%
-0.257819.44%
-0.00220.69%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf